Kiromic BioPharma Dirección

Dirección controles de criterios 0/4

El CEO de Kiromic BioPharma's es Pietro Bersani , nombrado en Jan 2022, tiene una permanencia de 1.42 años. compensación anual total es $697.49K, compuesta por 71.2% salario y 28.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 2.19% de las acciones de la empresa, por valor de €60.70K. La antigüedad media del equipo directivo y de la junta directiva es de 0.9 años y 2.7 años, respectivamente.

Información clave

Pietro Bersani

Chief Executive Officer (CEO)

US$697.5k

Compensación total

Porcentaje del salario del CEO	71.2%
Permanencia del CEO	1.4yrs
Participación del CEO	2.2%
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	2.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Pietro Bersani en comparación con los beneficios de Kiromic BioPharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2023	n/a	n/a	-US$33m
Dec 31 2022	US$697k	US$497k	-US$35m
Sep 30 2022	n/a	n/a	-US$39m
Jun 30 2022	n/a	n/a	-US$33m
Mar 31 2022	n/a	n/a	-US$29m
Dec 31 2021	US$336k	US$168k	-US$26m
Sep 30 2021	n/a	n/a	-US$19m
Jun 30 2021	n/a	n/a	-US$15m
Mar 31 2021	n/a	n/a	-US$22m
Dec 31 2020	US$63k	n/a	-US$20m

Compensación vs. Mercado: La compensación total de Pietro($USD697.49K) está por encima de la media de empresas de tamaño similar en el mercado German ($USD404.18K).

Compensación vs. Ingresos: La compensación de Pietro ha aumentado mientras la empresa no es rentable.

CEO

Pietro Bersani (55 yo)

1.4yrs

Permanencia

US$697,486

Compensación

Mr. Pietro Bersani, CPA, J.D., serves as Chief Executive Officer at Kiromic BioPharma, Inc. since May 10, 2022 and serves as Director since January 27, 2022. He serves as Principal Financial Officer at Kir...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Pietro Bersani	CEO, Principal Financial Officer & Director	1.4yrs	US$697.49k	2.19% $ 60.7k
Jason Morris	Chief Financial Officer	less than a year	sin datos	sin datos
Leonardo Mirandola	CSO & Interim COO	less than a year	sin datos	0.013% $ 373.5
Scott Dahlbeck	Chief of Staff	3.7yrs	US$442.12k	0% $ 0
Timothy Simkiss	Controller	less than a year	sin datos	sin datos

0.9yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 5JU0 no se considera experimentado ( 0.9 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Pietro Bersani	CEO, Principal Financial Officer & Director	3yrs	US$697.49k	2.19% $ 60.7k
Michael Nagel	Independent Chairperson of the Board	2.7yrs	US$214.20k	0.64% $ 17.8k
Ruggero De Maria	Member of Scientific Advisory Board	no data	sin datos	sin datos
Americo Cicchetti	Independent Director	3.3yrs	US$187.96k	0.64% $ 17.8k
Amorette Barber	Member of Scientific Advisory Board	no data	sin datos	sin datos
Martin D'Souza	Member of Scientific Advisory Board	no data	sin datos	sin datos
Sandeep Dhanda	Member of Scientific Advisory Board	no data	sin datos	sin datos
Luca Gattinoni	Member of Scientific Advisory Board	2.4yrs	sin datos	sin datos
Franco Locatelli	Member of Scientific Advisory Board	1.8yrs	sin datos	sin datos

2.7yrs

Permanencia media

56yo

Promedio de edad

Junta con experiencia: La junta directiva de 5JU0 no se considera experimentada (2.7 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Kiromic BioPharma Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Kiromic BioPharma, Inc., Annual General Meeting, Jun 26, 2024

Kiromic Biopharma, Inc. Announces Board Appointments

Kiromic BioPharma, Inc., Annual General Meeting, Jul 25, 2023

Kiromic Biopharma, Inc Appoints Brian Hungerford as Interim Chief Financial Officer

Kiromic BioPharma, Inc. Announces the Resignation of Dan Clark as Chief Financial Officer

Kiromic Biopharma, Inc. Announces Resignation of Karen Reeves as Director

Recent updates

Kiromic BioPharma, Inc. Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc., Annual General Meeting, Jun 26, 2024

Kiromic BioPharma, Inc. Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients

Kiromic Biopharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. Reports Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Deltacel-01 Clinical Trial

Kiromic BioPharma, Inc. Announces Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months

Kiromic Biopharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer

Kiromic Biopharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial

Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer

Nasdaq to Delist the Securities of Kiromic BioPharma

Kiromic Biopharma, Inc. Announces Deltacel™? Phase 1 Clinical Trial Enters Patient Recruitment Phase At Beverly Hills Cancer Center

Kiromic BioPharma, Inc.(OTCPK:KRBP) dropped from NASDAQ Composite Index

Kiromic BioPharma Common Stock to Begin Trading on the OTC Pink Sheets on September 14, 2023, Suspended from Trading on Nasdaq Capital Market

Kiromic Biopharma, Inc. Announces Board Appointments

Kiromic BioPharma, Inc. announced that it has received $2.4 million in funding

Kiromic BioPharma, Inc., Annual General Meeting, Jul 25, 2023

Kiromic Biopharma, Inc Appoints Brian Hungerford as Interim Chief Financial Officer

Kiromic BioPharma, Inc. Announces the Resignation of Dan Clark as Chief Financial Officer

Kiromic Biopharma, Inc. Announces Resignation of Karen Reeves as Director

Kiromic BioPharma Receives Non-Compliance Notice from Nasdaq

Frank Tirelli Resigns His Position as Director and Member of the Audit Committee, and the Nominating and Corporate Governance Committee of Kiromic Biopharma, Inc

High number of new and inexperienced directors

Kiromic BioPharma, Inc. announced that it has received $2 million in funding

Kiromic Biopharma Announces FDA Feedback from Type B Pre-Ind Meeting Confirms Deltacel Development Strategy

Gainey Mckenna & Egleston Files the First Class Action Lawsuit Against Kiromic Biopharma, Inc

Nasdaq Grants Extension to Kiromic BioPharma to Regain Compliance

The Klein Law Firm Announces Class Action Complaint Against Kiromic Biopharma, Inc

Gainey McKenna & Egleston Files Class Action Lawsuit Against Kiromic BioPharma, Inc

Kiromic BioPharma, Inc. Appoints Leonardo Mirandola as Chief Scientific Officer

High number of new and inexperienced directors

Kiromic BioPharma, Inc. Appoints Pietro Bersani to the Role of Chief Executive Officer, Effective May 10, 2022

Kiromic BioPharma, Inc. Announces Company Will Directly Submit Amended IND for Procel™ to the FDA in Second Half of 2022

Kiromic BioPharma, Inc., Annual General Meeting, Jun 22, 2022

Kiromic BioPharma, Inc. announced delayed annual 10-K filing

Kiromic BioPharma, Inc. Announces Board Appointments

High number of new and inexperienced directors

Kiromic BioPharma Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

High number of new and inexperienced directors

Kiromic BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $40 million.

Kiromic Announces FDA IND Submission First-In-Human, AI derived Off-The-Shelf IsoMesothelin Gamma Delta CAR T-cell Therapy

Kiromic Biopharma, Inc. Announces Identification of Novel Targets for Allogeneic Car Gamma Delta T-Cell Therapy in Solid Tumors Utilizing Kiromic’s Proprietary Artificial Intelligence Engine

Kiromic BioPharma, Inc. Announces FDA IND Submission Forty-Five Days before the end of the Second Quarter: First-In-Human, Off-The-Shelf Chimeric PD1 Switch Receptor - Gamma Delta T-cell Therapy

Kiromic Biopharma, Inc. to Resubmit Two Expanded INDs to the FDA for its Allogenic, Off-the-Shelf Gamma-Delta T cell Therapies for Multiple Solid Tumors

Kiromic Biopharma, Inc. Enters into A Strategic Alliance Agreement with Leon Office (H.K.) Ltd

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad